A gynecological preparation from Richter has received marketing authorization in Japan
The partner of Richter Gedeon Nyrt., Fuji Pharma Co., Ltd., received the marketing authorization for the Alyssa combination tablet developed in Japan. The approval means a milestone payment of 10 million euros for Richter’s 100 percent subsidiary, Estetra SRL, Richter announced on Tuesday on the website of the Budapest Stock Exchange.
The Alyssa combined tablet is a preparation for the treatment of dysmenorrhea – painful, crampy menstruation – which contains, among other things, a natural estrogen (estetrol), which has marketing rights in Japan and Southeast Asia.
In the Association of Nations (ASEAN) region, Fuji acquired it from Estetra SRL.
Fuji Alyssa is preparing to launch the combination pill under the trade name to provide a new treatment option for dysmenorrhoea patients.
Related news
Richter CEO: the company achieved good performance in the first quarter
Richter achieved a good performance in the first quarter and…
Read more >
Young people value sustainability and environmental protection the most
According to the a joint survey by the Bosch Group…
Read more >
According to a survey, young people value sustainability and environmental expectations the most
Young people primarily expect sustainability and the protection of environmental…
Read more >Related news
Viktor Orbán: we will introduce margin reduction for new products as well, if necessary
The margin regulation must be maintained because people must be…
Read more >
Who won and who lost in 2024? – Spectacular differences in results in food retail
The balance of the 2024 business year in the food…
Read more >
The domestic gin market is on the rise – According to SPAR, customers are increasingly aware and open to Hungarian brands
Gin sales have grown spectacularly in Hungarian retail in recent…
Read more >
